All Updates

All Updates

icon
Filter
Partnerships
Product updates
AQEMIA achieves research milestone in collaborative research with Servier in immuno-oncology
AI Drug Discovery
Jun 28, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jun 28, 2024

AQEMIA achieves research milestone in collaborative research with Servier in immuno-oncology

Partnerships
Product updates

  • AI-driven drug developer AQEMIA has announced a notable breakthrough in its joint research partnership with pharmaceutical company Servier. The company's study has identified molecules effective toward an undruggable target in immuno-oncology. This achievement will grant AQEMIA a milestone payment of an undisclosed amount.

  • The partnership was initiated in December 2021 to accelerate drug discovery in immuno-oncology using AQEMIA’s cutting-edge AI technology and deep physics. The company conducts research for several internal therapeutic programs in relevant fields such as oncology, immunology, inflammation, and neurological disorders.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.